Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LPCN
#3478
Lipocine Inc.
9.960
0
+4.73%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+4.73%
Monthly Change
-0.10%
6 month change
+243.45%
Year Change
+243.45%
Previous Close
9.510
0
Open
9.960
0
Bid
Ask
Low
9.960
0
High
9.960
0
Volume
6
Markets
US Stock Market
Healthcare
LPCN
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
5.35 M
5.35 M
5.35 M
5.42 M
5.55 M
—
Valuation ratios
Enterprise value
20.27 M
19.9 M
13.66 M
11.08 M
11.92 M
56.57 M
Price to earnings ratio
-5.83
—
-3.15
-3.67
-2.82
—
Price to sales ratio
3.04
2.36
4.69
4.06
3.57
14.68
Price to cash flow ratio
-4.87
-21.67
-3.05
-3.37
-2.96
-31.05
Price to book ratio
0.28
1.26
0.21
0.22
0.21
1.91
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.11
0.08
-0.09
-0.12
-0.2
-0.33
Return on equity %
-0.12
0.08
-0.1
-0.13
-0.23
-0.37
Return on invested capital %
-4 550.42
1 749.28
-1 668.85
-1 982.14
-2 859.92
-4 761.62
Gross margin %
0
100
100
100
100
400
Operating margin %
263.05 M
44.27
-2 226.82
-386.03
-2 933.51
-5 502.09
EBITDA margin %
—
—
—
—
—
—
Net margin %
221.88 M
51.04
-1 986.78
-354.13
-2 781.46
-5 071.33
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
12.97
14.75
15.64
12.71
8.25
51.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.16
0
0.03
0.01
0.2
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.53
0.31
-0.37
-0.35
-0.55
-0.96
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
3.71
3.99
3.69
3.35
2.8
13.82
Net current asset value per share
3.83
4.12
3.8
3.44
2.94
14.3
Tangible book value per share
3.57
3.87
3.59
3.2
2.61
13.27
Working capital per share
3.54
3.84
3.56
3.17
2.59
13.15
Book value per share
3.57
3.87
3.59
3.2
2.61
13.27
News
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Lipocine completes patient visits in phase 3 trial for PPD treatment
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress
Lipocine completes enrollment in phase 3 trial for PPD treatment
Lipocine’s PPD drug trial continues after positive safety review
Lipocine reaches 80% enrollment in postpartum depression drug trial
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Lipocine reports one-third enrollment in PPD treatment trial
Lipocine stock maintains Buy rating at H.C. Wainwright amid Phase 3 progress
Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential